Dr. James M. Luther MD, MSCI,is Associate Professor of medicine and pharmacology at Vanderbilt University School of Medicine in Nashville, Tennessee. His translational research program investigates the relationship between hypertension and its metabolic complications. He is director of the Vanderbilt Comprehensive Hypertension Center, where he evaluates and treats resistant and secondary causes of hypertension such as primary aldosteronism and renovascular hypertension. He is board certified in Internal Medicine and Nephrology and is a certified Hypertension Specialist.
Dr. Luther received his MD degree from Vanderbilt School of Medicine, where he completed training in Internal Medicine, Clinical Pharmacology, and Nephrology before joining the faculty in the Division of Clinical Pharmacology. He completed the Master in Clinical Investigation program, and now serves as coordinator for the Drug and Device Development course in this program.
Dr. Luther is a fellow of the American Heart Association (FAHA) and American Society of Nephrology (FASN). He has served on the ASN Hypertension Advisory Group and the AHA Program Committee of the Kidney in Cardiovascular Disease (KCVD) Council and is currently an Education Editor for the journal Hypertension. He has over 75 peer-reviewed publications (original articles, reviews, book chapters) and has served as a reviewer for over 30 peer-reviewed journals. He is co-editor of the upcoming Hypertension Secrets, 2nd ed.
Topic: MR antagonism for proteinuric kidney disease
Learning objectives:
Review the evidence supporting aldosterone’s role in mineralocorticoid receptor (MR) mediated kidney injury
Review pharmacology of currently available MR antagonists
Review the clinical evidence for MR antagonists in kidney disease, including diabetic nephropathy